Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS
· Delayed Price · Currency is USD
0.490
+0.110 (28.95%)
Nov 21, 2024, 4:00 PM EST
Seelos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 2.01 | 2.2 | - | - | - | 0.38 | Upgrade
|
| Cost of Revenue | 20.45 | 30.12 | 58.62 | - | - | 22.56 | Upgrade
|
| Gross Profit | -18.44 | -27.91 | -58.62 | - | - | -22.19 | Upgrade
|
| Selling, General & Admin | 11.39 | 12.59 | 12.3 | 15.02 | 7.78 | 5.56 | Upgrade
|
| Research & Development | -0.02 | - | - | 46.65 | 10.98 | - | Upgrade
|
| Operating Expenses | 11.37 | 12.59 | 12.3 | 61.67 | 18.76 | 5.56 | Upgrade
|
| Operating Income | -29.81 | -40.5 | -70.92 | -61.67 | -18.76 | -27.75 | Upgrade
|
| Interest Expense | -0.11 | -0.08 | -0.01 | -1.6 | -0.16 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.06 | 0.2 | 0.12 | 0.11 | 0.05 | 0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 39.38 | 13.69 | 0.29 | -0.89 | -0.22 | -21.52 | Upgrade
|
| EBT Excluding Unusual Items | 9.52 | -26.68 | -70.52 | -64.04 | -19.1 | -49.15 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -2 | Upgrade
|
| Other Unusual Items | -5.43 | -11.2 | -3.02 | -2.01 | - | -0.11 | Upgrade
|
| Pretax Income | 4.09 | -37.88 | -73.53 | -66.05 | -19.1 | -51.26 | Upgrade
|
| Earnings From Continuing Operations | 4.09 | -37.88 | -73.53 | -66.05 | -19.1 | -51.26 | Upgrade
|
| Net Income | 4.09 | -37.88 | -73.53 | -66.05 | -19.1 | -51.26 | Upgrade
|
| Net Income to Common | 4.09 | -37.88 | -73.53 | -66.05 | -19.1 | -51.26 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | 0 | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | 0 | - | Upgrade
|
| Shares Change (YoY) | 191.24% | 38.20% | 17.03% | 103.03% | - | - | Upgrade
|
| EPS (Basic) | 47.06 | -989.53 | -2654.56 | -2790.49 | -1638.45 | - | Upgrade
|
| EPS (Diluted) | 47.06 | -989.53 | -2654.72 | -2790.49 | -1638.45 | - | Upgrade
|
| Free Cash Flow | -13.27 | -23.91 | -61.6 | -49 | -20.91 | -19.31 | Upgrade
|
| Free Cash Flow Per Share | -152.70 | -624.61 | -2223.89 | -2070.01 | -1793.88 | - | Upgrade
|
| Operating Margin | -1480.04% | -1838.36% | - | - | - | -7399.20% | Upgrade
|
| Profit Margin | 203.13% | -1719.56% | - | - | - | -13668.00% | Upgrade
|
| Free Cash Flow Margin | -659.09% | -1085.43% | - | - | - | -5148.00% | Upgrade
|
| EBITDA | - | - | - | - | - | -27.71 | Upgrade
|
| D&A For EBITDA | - | - | - | - | - | 0.04 | Upgrade
|
| EBIT | -29.81 | -40.5 | -70.92 | -61.67 | -18.76 | -27.75 | Upgrade
|
| Revenue as Reported | 2.01 | 2.2 | - | - | - | 0.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.